MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Applied Genetic Technologies Corp Company Profile (NASDAQ:AGTC)

Consensus Ratings for Applied Genetic Technologies Corp (NASDAQ:AGTC) (?)
Ratings Breakdown: 8 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $29.14 (124.87% upside)

Analysts' Ratings History for Applied Genetic Technologies Corp (NASDAQ:AGTC)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016Cantor FitzgeraldReiterated RatingBuy$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016Wells FargoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/10/2016WedbushReiterated RatingOutperform$36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/25/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/18/2016Janney Montgomery ScottInitiated CoverageBuy$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/9/2016Stifel NicolausLower Price TargetBuy$32.00 -> $29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/10/2016Chardan CapitalReiterated RatingBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/3/2014WunderlichReiterated RatingBuy$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Applied Genetic Technologies Corp (NASDAQ:AGTC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
9/8/2016        
5/9/2016Q3$0.05$0.11$12.98 million$12.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/8/2016Q216($0.19)$0.17$8.76 million$12.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q1($0.19)($0.53)$5.91 million$11.06 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/10/2015Q415($0.41)($0.48)$0.71 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q315($0.33)($0.38)$0.59 million$0.28 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2015Q215($0.39)($0.28)$0.65 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q115($0.29)($0.34)$258.00 million$705.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/26/2014Q414($0.35)($0.32)$0.12 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014Q114($0.37)($25.45)$0.15 million$0.23 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Applied Genetic Technologies Corp (NASDAQ:AGTC)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20162($0.02)$0.00($0.01)
Q1 20171($0.09)($0.09)($0.09)
Q2 20171($0.13)($0.13)($0.13)
Q3 20171($0.03)($0.03)($0.03)
Q4 20171($0.05)($0.05)($0.05)
(Data provided by Zacks Investment Research)
Dividend History for Applied Genetic Technologies Corp (NASDAQ:AGTC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Applied Genetic Technologies Corp (NASDAQ:AGTC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/23/2015Plc GlaxosmithklineMajor ShareholderSell503,150$22.00$11,069,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2015Daniel L MenichellaVPSell1,996$24.90$49,700.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/22/2014Daniel L MenichellaVPSell9,000$20.83$187,470.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Interwest Partners Viii LpMajor ShareholderBuy75,376$12.00$904,512.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Jill CarrollDirectorBuy103,762$12.00$1,245,144.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Applied Genetic Technologies Corp (NASDAQ:AGTC)
DateHeadline
06/27/16 07:08 AMShare Update and Earnings Review for Applied Genetic Technologies Corporation (NASDAQ:AGTC) - Press Telegraph
06/27/16 07:08 AMApplied Genetic Technologies Corporation (AGTC) Broker Price Targets For The Coming Week - Fiscal Standard
06/24/16 02:21 PMApplied Genetic Technologies Corporation (NASDAQ:AGTC) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 02:21 PMCovering the Bases on Applied Genetic Technologies Corporation (NASDAQ:AGTC): Where is the Stock Going? - Press Telegraph
06/24/16 02:21 PMApplied Genetic Technologies Corporation (AGTC) is Trading Lower on Unusual Volume for June 22 - Equities.com
06/23/16 10:06 AMAchromatopsia - Pipeline Review, H1 2016 Featuring Amgen & Applied Genetic Technologies Corporation - Research and Markets
06/21/16 02:21 PMApplied Genetic Technologies Corporation (AGTC) Current Analyst Ratings - Fiscal Standard
06/19/16 07:07 AMApplied Genetic Technologies Corporation (AGTC) Analyst Price Targets For The Coming Week - Fiscal Standard
06/15/16 07:28 PMCan Applied Genetic Technologies Corporation (NASDAQ:AGTC) Meet Analysts Expectations? - Stocks Daily
06/09/16 08:17 PMAGTC to Host Research Day on June 21, 2016 in New York - GlobeNewswire (press release)
06/09/16 02:22 PMApplied Genetic Technologies Corp.: AGTC to Host Research Day on June 21, 2016 in New York - The Wall Street Transcript
06/09/16 11:15 AMAGTC to Host Research Day on June 21, 2016 in New York - Nasdaq
06/09/16 06:19 AMAGTC to Host Research Day on June 21, 2016 in New York - [at noodls] - GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 09, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated ...
06/08/16 02:49 PMAGTC receives orphan medicinal product designation for retinitis pigmentosa gene therapy in Europe
06/07/16 02:21 PMAGTC Announces Orphan Medicinal Product Designation in the European Union for Gene Therapy to Treat X-linked ... - GlobeNewswire (press release)
06/07/16 06:18 AMAGTC Announces Orphan Medicinal Product Designation in the European Union for Gene Therapy to Treat X-linked Retinitis Pigmentosa - [at noodls] - GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 07, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated ...
06/05/16 07:39 PMAfter Last Week What Do Analysts Think Of Applied Genetic Technologies Corporation (AGTC) - Share Trading News
06/03/16 10:51 AMShare Rating Focus on Applied Genetic Technologies Corporation (NASDAQ:AGTC) - HNN
06/02/16 08:22 PMStrong Sell Calls Count For Applied Genetic Technologies Corporation (NASDAQ:AGTC) At 0 - Investor Newswire - Strong Sell Calls Count For Applied Genetic Technologies Corporation (NASDAQ:AGTC) At 0Investor NewswireApplied Genetic Technologies Corporation (NASDAQ:AGTC) has a total of 7 Strong Buy calls and 0 Strong Sell advises as of 2016-06-01. Zacks uses a rating procedure which assigns scores to stocks on a narrow 1-5 scale. When a stock gets a score of 1 or 2 ...and more »
06/02/16 11:02 AMCould Applied Genetic Technologies Corp Gain Strenght? The Stock Reaches 52-Week Low - HNN - Could Applied Genetic Technologies Corp Gain Strenght? The Stock Reaches 52-Week LowHNNThe stock of Applied Genetic Technologies Corp (NASDAQ:AGTC) is a huge mover today! The stock decreased 3.37% or $0.58 during the last trading session, hitting $16.62. About 85,796 shares traded hands. Applied Genetic Technologies Corp ...
06/02/16 11:02 AMApplied Genetic Technologies Corporation (NASDAQ:AGTC) Stock Update & Estimates - Stock Tick Tock - Applied Genetic Technologies Corporation (NASDAQ:AGTC) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Applied Genetic Technologies Corporation (NASDAQ:AGTC) to post earnings of $0.06 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will ...and more »
05/26/16 10:45 AMTarget Check and Stock Performance Recap Applied Genetic Technologies Corporation (NASDAQ:AGTC) - Wall Street Hints and News - Target Check and Stock Performance Recap Applied Genetic Technologies Corporation (NASDAQ:AGTC)Wall Street Hints and NewsIn recent session activity, Applied Genetic Technologies Corporation (NASDAQ:AGTC) shares have traded -0.06%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the ...and more »
05/26/16 10:45 AMIt Seems Applied Genetic Technologies Corp Will Go Up. Have Big Gap Up Today - Wall Street Hints and News - It Seems Applied Genetic Technologies Corp Will Go Up. Have Big Gap Up TodayWall Street Hints and NewsThe stock of Applied Genetic Technologies Corp (NASDAQ:AGTC) gapped up by $0.08 today and has $28.11 target or 76.00% above today's $15.97 share price. The 8 months technical chart setup indicates low risk for the $296.83 million company. The gap ...and more »
05/24/16 01:43 PMETF’s with exposure to Applied Genetic Technologies Corp. : May 24, 2016 -
05/17/16 12:48 PMApplied Genetic Technologies Corp. :AGTC-US: Earnings Analysis: Q3, 2016 By the Numbers -
05/12/16 03:11 PMAPPLIED GENETIC TECHNOLOGIES CORP Files SEC form 8-K, Change in Directors or Principal Officers -
05/09/16 04:25 PMApplied Genetic Technologies posts 3Q profit -
05/09/16 03:28 PMAGTC Announces Financial Results for the Quarter Ended March 31, 2016 - [at noodls] - GAINESVILLE, Fla., and CAMBRIDGE, Mass., May 09, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated ...
05/09/16 06:07 AMQ3 2016 Applied Genetic Technologies Corp Earnings Release - After Market Close -
05/05/16 06:00 AMInvestigational Gene-Based Therapy for Alpha-1 Antitrypsin (AAT) Deficiency Demonstrates Durable Response at Five Years - [GlobeNewswire] - WASHINGTON, May 05, 2016-- Researchers from the University of Massachusetts Medical School today announced new data evaluating the efficacy of an investigational adeno-associated virus vector gene therapy ...
05/02/16 06:00 AMNovel Investigational Gene-Based Therapy for X-Linked Retinitis Pigmentosa Demonstrates Functional Rescue of Photoreceptor Structure and Function in Canine Model - [GlobeNewswire] - SEATTLE, May 02, 2016-- Researchers from the University of Pennsylvania today announced new animal study data evaluating the efficacy of an investigational adeno-associated virus vector gene therapy treatment ...
04/29/16 06:31 AMAGTC Announces Participation & Presentations at Upcoming Scientific & Investor Conferences - [at noodls] - GAINESVILLE, Fla., and CAMBRIDGE, Mass., April 29, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated ...
04/22/16 06:54 AMApplied Genetic Technologies Offers Data Evaluating Novel AAV-Based Gene Therapy as Potential Treatment for LCA, SECORD - Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced data evaluating an experimental recombinant AAV vector gene delivery in patients with Leber congenital amaurosis (LCA) or severe early-childhood-onset retinal degeneration (SECORD), two related retinal diseases caused by mutations in the RPE65 gene that cause severe loss of vision in infancy. Results from the study, entitled "Results at 2 Years after Gene Therapy for RPE65-deficient Leber Congenital Amaurosis and Severe Early-Childhood Onset Retinal Dystrophy," were published online in the peer-reviewed journal Ophthalmology and will appear in the April print issue of the journal. "LCA and SECORD are serious retinal degenerative conditions with no current treatments that can lead to total blindness and significantly impair quality of life in affected individuals," said contributing study author Jeff Chulay, M.D., DTM&H, Vice President and Chief ...Full story available on Benzinga.com
03/14/16 11:24 AMEarnings Outlook For Applied Genetic Technologies Corporation (NASDAQ:AGTC) - Investor Newswire - Earnings Outlook For Applied Genetic Technologies Corporation (NASDAQ:AGTC)Investor NewswireThe first method that the company applies is to plan surveys of Wall Street analysts at regular intervals and then derive an average rating on the stock. As per the recent poll, Applied Genetic Technologies Corporation (NASDAQ:AGTC) can post EPS of $-0 ...and more »
03/07/16 03:01 PMAGTC to Participate in Upcoming Investor and Scientific Conferences - [GlobeNewswire] - GAINESVILLE, Fla., and CAMBRIDGE, Mass., March 07, 2016-- Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus- based gene therapies ...
03/03/16 07:32 AMIs Applied Genetic Technologies (AGTC) Stock a Solid Choice Right Now? -
02/26/16 09:42 AMApplied Genetic Technologies Corp (AGTC) Drops 5.35% on February 25 - Equities.com - Applied Genetic Technologies Corp (AGTC) Drops 5.35% on February 25Equities.comApplied Genetic Technologies Corp (AGTC) was one of the Russell 2000's biggest losers for Thursday February 25 as the stock slid 5.35% to $14.06, a loss of $-0.795 per share. Starting at an opening price of $14.87 a share, the stock traded between $13 ...Is Selling Applied Genetic Technologies Corp Here a Winning Strategy?Business Standard Tribuneall 2 news articles »
02/26/16 09:42 AMApplied Genetic Technologies Corporation (AGTC) Analyst Updates - Risers & Fallers - Applied Genetic Technologies Corporation (AGTC) Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Applied Genetic Technologies Corporation (AGTC). According to the latest broker reports outstanding on Friday 26th of February, 3 analysts have a rating of “strong ...
02/26/16 07:45 AMShould Applied Genetic Technologies (AGTC) Be On Your Radar Now? -
02/21/16 01:10 PMAGTC Selected to the University of Florida's 2016 Gator100 - Nasdaq - AGTC Selected to the University of Florida's 2016 Gator100NasdaqGAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 19, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene ...and more »
02/17/16 01:42 PMAGTC Opens New Florida Office-Lab Facility - Applied Genetic Technologies Corporation (AGTC), said today it has opened a new combined-use corporate office and laboratory in Alachua, FL. AGTC's new facility, within a multi-tenant site, consists of approximately 20,000 square feet that includes lab and ...
02/16/16 03:01 PMAGTC CEO to Present at the RBC Capital Markets Global Healthcare Conference on February 23, 2016 - [GlobeNewswire] - GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 16, 2016-- Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus- based gene therapies ...
02/16/16 01:00 PMApplied Genetic Technologies Corp. Earnings Analysis: Q2, 2016 By the Numbers -
02/12/16 01:23 PMStifel Nicolaus Maintains Applied Genetic Technologies Corp to Buy with Price Target $29.00 - Street Edition - Stifel Nicolaus Maintains Applied Genetic Technologies Corp to Buy with Price Target $29.00Street EditionBrokerage firm Stifel Nicolaus Maintains its rating on Applied Genetic Technologies Corp(NASDAQ:AGTC). In a research note issued to the investors, the brokerage major Lowers a price-target of $29.00 per share. The shares have been rated Buy. The rating ...
02/11/16 01:14 PMApplied Genetic Technologies Corporation (AGTC) Recent Analyst Updates - Risers & Fallers - Applied Genetic Technologies Corporation (AGTC) Recent Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Applied Genetic Technologies Corporation (AGTC). According to the latest broker reports outstanding on Thursday 11th of February, 4 analysts have a rating of “strong ...Revenue Update on Applied Genetic Technologies Corp(NASDAQ:AGTC)Street EditionApplied Genetic Technologies Receives a Buy from Roth CapitalAnalyst Ratingsall 4 news articles »
02/09/16 12:41 PMApplied Genetic Technologies' (AGTC) CEO Sue Washer on Q2 2016 Results - Earnings Call Transcript - We believe that Synpromics' proprietary technology platform has ... our portfolio of treatment for genetic diseases with our adaptable gene therapy platform in both, ophthalmic and non-ophthalmic conditions. AGTC has several research stage gene therapy ...
02/08/16 03:22 PMApplied Genetic Technologies posts 2Q profit -
02/08/16 03:12 PMAPPLIED GENETIC TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statem -
02/08/16 03:08 PMAPPLIED GENETIC TECHNOLOGIES CORP Files SEC form 10-Q, Quarterly Report -
02/08/16 03:01 PMAGTC Announces Financial Results for the Quarter Ended December 31, 2015 - [GlobeNewswire] - GAINESVILLE, Fla., and CAMBRIDGE, Mass., Feb. 08, 2016-- Applied Genetic Technologies Corporation, a biotechnology company conducting human clinical trials of adeno-associated virus- based gene therapies ...
About Applied Genetic Technologies Corp

Applied Genetic Technologies Corp logoApplied Genetic Technologies Corp is a United States-based clinical stage biotechnology company. The Company develops gene therapy products for the treatment of inherited and acquired diseases. Its products are used to treat Alpha One Antitrypsin Deficiency (Alpha-1), a respiratory disease caused by deficiencies in the tissue protective protein alpha one antitrypsin; and Lebers congenital amaurosis, an inherited condition causing early blindness. Its products also used to treat X-linked retinoschisis, an inherited form of retinal degeneration affecting young males with poor vision either in infancy or at school age; and achromatopsia, an inherited condition that is associated with color blindness, visual acuity loss, and extreme light sensitivity resulting in daytime blindness.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AGTC
  • CUSIP:
Key Metrics:
  • Previous Close: $13.64
  • 50 Day Moving Average: $15.35
  • 200 Day Moving Average: $15.57
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $233.71M
  • Current Quarter EPS Consensus Estimate: $-0.16 EPS
Additional Links:
Applied Genetic Technologies Corp (NASDAQ:AGTC) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha